EUVIMEDEUVIMED entdecken
Crossref

Targeted LC–MS/MS‐Based Serum Nucleoside Metabolomics for Early Detection and Biomarker Discovery in Colorectal Cancer

Ramzy Rashed iD, Mostafa Abdelglil iD, Ghada Salama iD

Biomedical Chromatography · 2026-05 · 40 (5)

DOI: 10.1002/bmc.70439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 02.04.2026. Verfasst von Ramzy Rashed und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Al-Farahidi University, Baghdad, Iraq. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Biomarkers, Tumor. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a leading cause of cancer‐related morbidity and mortality worldwide, and early detection remains essential for improving patient outcomes. This study evaluated the diagnostic potential of targeted serum nucleoside metabolomic profiling, alone and in combination with established tumor markers (CEA and CA19‐9). Serum samples from 50 CRC patients and 25 healthy controls were analyzed using a validated LC–MS/MS platform. Sample preparation and analytical conditions were optimized using a design of experiment (DoE) approach. Multivariate analysis was performed using partial least squares–discriminant analysis (PLS‐DA), and diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis. CRC patients showed increased purine metabolites and modified nucleosides (adenosine, inosine, xanthine, hypoxanthine, and N 6 ‐methyladenosine) and decreased cytidine and uridine ( p < 0.01). The metabolomic panel showed strong discrimination (AUC = 0.91; sensitivity = 88%; specificity = 86%). Conventional markers showed moderate performance (CEA: AUC = 0.83; CA19‐9: AUC = 0.79). Combined analysis improved performance (AUC = 0.95; sensitivity = 92%; specificity = 89%). Targeted serum nucleoside profiling enhances CRC detection and improves diagnostic accuracy when integrated with conventional tumor markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryBiomarkers, TumorMetabolomicsNucleosidesHumansMaleReproducibility of ResultsFemaleMiddle AgedSensitivity and SpecificityMetabolomeAgedEarly Detection of CancerCase-Control StudiesAdultChromatography, LiquidLinear Models

Stichwörter der Autor:innen

Design‐Expert optimizationLC–MS/MSPLS‐DAROC analysisbiomarker discoverycolorectal cancernucleoside metabolomics

Substanzen

Biomarkers, TumorNucleosides

Autor:innen und Institutionen

  • College of Pharmacy, Al-Farahidi University, Baghdad, Iraq.
  • Department of Medical Laboratory Techniques, Al-Farahidi University, Baghdad, Iraq.
  • Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.

ORCID-Profile: Ramzy Rashed, Mostafa Abdelglil, Ghada Salama

Zitieren

APA

Rashed, R., Abdelglil, M., & Salama, G. (2026). Targeted LC–MS/MS‐Based Serum Nucleoside Metabolomics for Early Detection and Biomarker Discovery in Colorectal Cancer. Biomedical Chromatography, 40(5). https://doi.org/10.1002/bmc.70439

Vancouver

Rashed R, Abdelglil M, Salama G. Targeted LC–MS/MS‐Based Serum Nucleoside Metabolomics for Early Detection and Biomarker Discovery in Colorectal Cancer. Biomedical Chromatography. 2026;40(5). doi:10.1002/bmc.70439

BibTeX
@article{Rashed2026,
  author = {Rashed, Ramzy and Abdelglil, Mostafa and Salama, Ghada},
  title = {Targeted LC–MS/MS‐Based Serum Nucleoside Metabolomics for Early Detection and Biomarker Discovery in Colorectal Cancer},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {5},
  doi = {10.1002/bmc.70439}
}
Kostenlos starten →